Dr. Lal PathLabs has announced a Board meeting scheduled for Thursday, April 30, 2026, to approve the Audited Standalone and Consolidated Financial Results for the Quarter and Full Financial Year ending March 31, 2026. Consequently, the company will observe a closure of the Trading Window for dealings in securities, effective from April 1, 2026, through May 2, 2026.
Announcement of Board Meeting Date
A significant meeting of the Board of Directors of Dr. Lal PathLabs Limited has been formally scheduled to take place on Thursday, April 30, 2026. The primary agenda item for this session is to review, consider, and approve the Audited Financial Results of the Company. These results will encompass both the Standalone and Consolidated figures for the financial quarter, as well as the entire Financial Year ending on March 31, 2026.
Closure of Trading Window Implemented
In alignment with established corporate governance guidelines, the company has also notified the mandatory closure of the Trading Window concerning the dealing in the Company’s Securities. This restriction will commence at the start of the new financial period, specifically from April 1, 2026. The window is set to reopen on May 2, 2026, meaning the closure period spans 33 days (inclusive of both specified dates).
Key Corporate Filings Overview
This intimation serves as compliance under Regulation 29 of the relevant Listing Obligations and Disclosure Requirements. The company, trading under the Symbol LALPATHLAB on the National Stock Exchange and Scrip Code 539524 on the BSE, has requested that stakeholders take this information on record.
Source: BSE
